


Exhibit D

Hydrocortisone Acetate Lotion USP

DESCRIPTION

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Hydrocortisone acetate is a member of this class. Hydrocortisone Acetate has a molecular formula of $C_{23}H_{32}O_6$, a molecular weight of 404.50, and a CAS registry number of 50-03-3. The chemical name is: Pregn-4-ene-3,20-dione,21-(acetyloxy)-11, 17-dihydroxy-, (11 β)- and the chemical structural formula is presented below:



Hydrocortisone Acetate Lotion is a topical preparation containing hydrocortisone acetate 2.5% w/w in a water washable lotion containing the following inactive ingredients: stearic acid, cetyl alcohol, polyoxyl 40 stearate, diisopropyl adipate, dimethicone, trolamine, povidone, potassium sorbate, sorbic acid, glycerin, petrolatum, lanolin, hydrogenated coconut oil, sorbitan sesquiolate, stearyl alcohol, and purified water.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, anti-pruritic, and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressing substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressing may be a valuable therapeutic adjunct for the treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION.)

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroid and thus be more susceptible to systemic toxicity. (See PRECAUTIONS - Pediatric Use.)

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing.

5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garment may constitute occlusive dressings.

Laboratory Tests: The following tests may be helpful in evaluating the HPA axis suppression:

- Urinary free cortisol test
- ACTH stimulation test

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy. Teratogenic Effects. Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged period of time.

Nursing Mothers: It is not know whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use: *Pediatric patients may demonstrate greater susceptibility to topical corticosteroid induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface to body weight ratio.*

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasm cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS:

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressing. These reaction are listed in an approximate decreasing order of occurrence:

- | | | |
|------------|---------------------------|---------------------|
| Burning | Hypertichosis of the skin | Maceration |
| Itching | Acneiform eruptions | Secondary infection |
| Irritation | Hypopigmentation | Skin atrophy |

Dryness
Folliculitis

Perioral dermatitis
Allergic contact dermatitis

Striae
Miliaria

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS.)

DOSAGE AND ADMINISTRATION

Topical corticosteroids are generally applied to the effected areas as a thin film two to four times daily depending on the severity of the condition.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the used of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

fl.oz. bottle (NDC xxxx-xxxx-xx)

fl.oz. bottle (NDC xxxx-xxxx-xx)

R Only.

Store at controlled room temperature 15°C - 30°C (59°F - 86°F).

FERNDAL LABORATORIES, INC.

Ferndale, Michigan 48220

Iss.

Attach the Airborne Express Label

Place sticker here if necessary

FROM		72973706		Payment	Origin	PTK 5677508325		
FERNDALE LABS INC 780 W 8 MILE RD FERNDALE, MI 48220				Bill to: Receiver <input type="checkbox"/> 3rd Party <input type="checkbox"/>	AIRBORNE EXPRESS		EXP (Letter - 150 lbs)	
Deh. Therese 248-548-0900				<input type="checkbox"/> Paid in Advance	Billing Reference will appear on invoice HCA Lot # 2,590		NAS (Letter - 5 lbs)	
TO DOCKETS MGMT BRANCH FDA - DEPT OF HEALTH + HUMAN SVCS. 5630 Fishers Lane Rockville MD 20852 Room 1061				# of Pkgs 1	Weight (LBS)	Packaging Letter Express <input type="checkbox"/>	One box must be checked Express Pack <input type="checkbox"/> Other Packaging <input type="checkbox"/>	
				Special Instructions		<input type="checkbox"/> SAT	<input type="checkbox"/> HAA	
						<input type="checkbox"/> LAB	<input type="checkbox"/>	
				5 6 7 7 5 0 8 3 2 5		PEEL BACK FROM 567 750 8325		
011 AIRBORNE EXPRESS PACKAGE LABEL				5677508325				

MLDA 4X ABH



United States Shipping

1. Complete applicable white sections of the U.S. Airbill. Sign and date the Airbill at the Sender's Signature line. Please press hard.
2. Peel off protective covering from back of Airbill.
3. Affix Airbill to envelope within dotted lines shown.
4. When using a Drop Box - follow special instructions on the Drop Box.



International Shipping

Includes Canada & Puerto Rico

Limitation on Contents

The maximum acceptable contents of a Letter Express is forty (40) 8-1/2 x 11 pages. If the gross weight of the contents, envelope and airbill exceeds 1/2 pound, the next higher rate will apply. Contents must be of a size and shape which fit the envelope and allow it to be securely sealed without damage. Cash or cash equivalent should not be shipped. Items of high intrinsic value should not be shipped in Letter Express packaging.

Limitations of Liability